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1. Introduction 
Multiple myeloma (MM) is a malignant B-cell disease, characterized by uncontrolled 
proliferation of differentiated plasma cells in bone marrow (BM), osteolytic bone lesions, 
monoclonal protein peaks in serum or urine and suppression of normal antibody 
production. Patients with MM usually present with a number of clinical signs and 
symptoms, including fatigue, infection, severe bone pain, bone fractures, hypercalcaemia, 
and renal disease (Bommert et al., 2006; Raman et al., 2007; Redzepovic et al., 2008). Despite 
clinical responses produced by conventional chemotherapy, radiotherapy, and an increasing 
number of new compounds and improvements in supportive therapy, MM remains largely 
incurable (Katzel et al., 2007; Ozdemir et al., 2004; Redzepovic et al., 2008). 
Tumor necrosis factor-ǂ (TNF-ǂ) is a known survival and proliferation factor for myeloma 
cell lines. It is produced by tumor and stromal cells in BM of patients with MM and induces 
tumor cell proliferation, migration, survival, drug resistance, and blood vessel proliferation 
(Harrison et al., 2006; Jourdan et al., 1999). Although TNF-ǂ secreted by MM cells does not 
induce significant growth and drug resistance in tumor cells, it stimulates interleukin-6 (IL-
6) secretion in bone marrow stromal cells more potently than vascular endothelial growth 
factor (VEGF) or transforming growth factor-ǃ (TGF-ǃ) (Yasui et al., 2005). Out of BM 
environment, circulating TNF-ǂ levels are increased in MM patients with manifest bone 
disease, whose osteoblasts constitutively overexpress receptors for TNF-related apoptosis-
inducing ligand, intercellular adhesion molecule-1 (ICAM-1), and monocyte chemotactic 
protein-1 (MCP-1) (Silvestris et al., 2004). 
In our previous study, treatment with native human leukocyte interferon-ǂ (nhIFN-ǂ), 
recombinant human interferon-ǂ2a (rhIFN-ǂ2a) and recombinant human interferon-ǂ2b 
(rhIFN-ǂ2b) in doses of 500 IU/ml, 1000/ml and 2000 IU/ml resulted in differential effects on 
P3-X63-Ag8.653 mouse myeloma cells. A statistically significant dose-dependent decrease in 
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cell viability was observed in P3-X63-Ag8.653 mouse myeloma cells treated with nhIFN-ǂ in 
comparison with matched negative controls. Conversely, a statistically significant increase in 
cell viability was observed in P3-X63-Ag8.653 mouse myeloma cells treated with rhIFN-ǂ2a 
and rhIFN-ǂ2b. This increase in cell viability occurred only in relation to their matched 
negative controls and was not dose-dependent (Plesničar et al., 2009). The differences in effects 
on P3-X63-Ag8.653 mouse myeloma cell viability between nhIFN-ǂ and recombinant 
interferons probably occurred because nhIFN-ǂ is composed of many subtypes of nhIFN-ǂ 
and also contains trace amounts of IFN-Ǆ, TNF-ǂ, TNF-ǃ, interleukin (IL)-1ǂ, IL-1ǃ, IL-2, IL-6, 
granulocyte-macrophage colony-stimulating factor and platelet-derived growth factor. 
Therefore, the decrease of cell viability in nhIFN-ǂ treated P3-X63-Ag8.653 mouse myeloma 
cell cultures may have occurred in consequence of a synergistic effect of the various cytokines 
in nhIFN-ǂ preparation. The quantities and the synergistic effect of the cytokines in nhIFN-ǂ 
preparation are very small at lower concentrations and probably become active only at higher 
concentrations, thus accounting for the dose-dependent effects observed on cell growth 
(Plesničar et al., 2009; Šantak et al., 2007, Zidovec & Mažuran, 1999). In contrast to nhIFN-ǂ, 
rhIFN-ǂ2a and rhIFN-ǂ2b are each preparations of only one subtype of IFN-ǂ. The increase in 
cell viability in P3-X63-Ag8.653 mouse myeloma cell culture groups treated with rhIFN-ǂ2a 
and rhIFN-ǂ2b in our study was in accordance with a number of reports suggesting that IFN-ǂ 
could induce uncontrolled cell proliferation in some patients with MM (Plesničar et al., 2009; 
Puthier et al., 2001; Sawamura et al., 1992). Interferon-ǂ has been recognized as a survival 
factor in MM in some studies, the data supporting this claim are based on the results of studies 
using recombinant interferons-ǂ (Cheriyath et al., 2007; Ferlin-Bezombes et al., 1998; Puthier et 
al., 2001). 
The P3-X63-Ag8.653 mouse myeloma cell line is routinely cultured in several types of 
growth media. The cells in P3-X63-Ag8.653 mouse myeloma cell line propagate in 
suspension and do not secrete immunoglobulin. They can be used as fusion partners for 
producing hybridomas and show lymphocyte-like morphology (Kearney et al., 1979). 
Human myeloma blood cells were described as carrying surface membrane monoclonal or 
idiotypic immunoglobulin structures, and were morphologically classified as atypical small 
to medium-sized lymphocytes, lymphoblasts, lymphoplasmacytoid, plasmacytoid cells or 
myeloma cells (Mellstedt et al., 1984). With regard to morphology and despite the 
differences, it may be possible that P3-X63-Ag8.653 mouse myeloma cells, growing in 
suspension cell cultures, share at least some common properties with circulating clonogenic 
CD19 positive and CD138 negative cells, described as phenotypically resembling mature B 
cells (Cremer et al., 2001; Matsui et al., 2004). 
The aim of the present study was to compare the effects of different doses of rTNF-ǂ on the 
in-vitro growth of P3-X63-Ag8.653 mouse myeloma cells. Additionally, in one cell culture 
study group the aim was also to compare the effect of a combination of rTNF-ǂ and nhIFN-
ǂ with the effects of corresponding doses of single cytokines on the in-vitro growth of P3-
X63-Ag8.653 mouse myeloma cells. 
2. Materials and methods 
2.1 P3-X63-Ag8.653 mouse myeloma cell preparation 
The P3-X63-Ag8.653 mouse myeloma cells were retrieved from the frozen storage at -80 °C 
and cultured in 25 cm² cell culture flasks (Cole Parmer, Vernon Hills, IL, USA) in Dulbecco's 
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modified Eagle's medium (Sigma-Aldrich, St. Louis, MO, USA), supplemented with 10% 
fetal calf serum (FCS) (Sigma-Aldrich, St. Louis, MO, USA) and gentamycin (Krka, tovarna 
zdravil, d. d., Novo Mesto, Slovenia). The cells were incubated at 37 °C in a humidified 
atmosphere of 5% CO₂ for 48 hours.  
In preparation for this study, P3-X63-Ag8.653 mouse myeloma cell growth curves on 
logarithmic scale plots were established when the most convenient seeding density to be 
used was determined. Various time zero values ranged from 5 X 103 to 6 X 104 cells/ml and 
S-shaped growth curves were observed after cell concentrations measured in 24 hour 
intervals over the 96 hours were plotted on Keuffel & Esser 464970 Semi-Logarithmic Grids 
general purpose drawing paper. Time zero density of 104 P3-X63-Ag8.653 mouse myeloma 
cells/ml was found to be the most appropriate for the study. With the use of Keuffel & Esser 
464970 graph paper it was also possible to observe that P3-X63-Ag8.653 mouse myeloma 
cells started to enter the log phase in approximately 24 hours (one day) and the plateau 
phase in approximately 72 hours (three days). 
2.2 Recombinant human tumor necrosis factor-α, native human interferon-α and cell 
culture study groups 
Actively growing P3-X63.Ag8.653 mouse myeloma cells were seeded into 35 mm Petri 
dishes (Becton Dickinson, Franklin Lakes, NJ, USA) and incubated in each study group with 
three different concentrations of rTNF-ǂ (Prospecbio, East Brunswick, NJ, USA). In the first 
study group the cells were incubated with 2, 10 and 20 IU/ml of rTNF-ǂ, in the second with 
30, 40 and 50 IU/ml of rTNF-ǂ, in the third with 100, 200 and 300 IU/ml of rTNF-ǂ, and in 
the fourth study group with 400, 800 and 1200 IU/ml of rTNF-ǂ. After the experiments with 
rTNF-ǂ, in one study group the cells were incubated with a combination of 10 IU/ml of 
rTNF-ǂ and 2000 IU/ML of nhIFN-ǂ (Institute of Immunology Inc., Zagreb, Croatia). The 
combination was compared to the corresponding doses of single cytokines. Matched 
negative controls that consisted of P3-X63-Ag8.653 mouse myeloma cells cultured in the 
absence of cytokines were established for each of the different cytokine study groups. All 
experiments were replicated five times and 20 Petri dishes were used for each cytokine cell 
culture study group and their negative controls. Cell viability was assessed by Trypan blue 
exclusion in 24 hour intervals (days 1-4). 
2.3 Statistical analysis 
In proliferating cell lines, it is difficult to distinguish between early cell loss and prolonged 
lag phase in which cells are still adapting to their new environment (Wilson, 1994). The 
effects of different concentrations of rTNF-ǂ and its combination with nhIFN-ǂ were thus 
estimated with the use of whole growth curves to reduce the possibility of 
misinterpretation. Statistical evaluation was performed using SPSS® software package, 
version 12.0 (SPSS Inc., Chicago, IL, USA) for Windows®. Analysis of variance (ANOVA) 
was used to assess the differences between and within different treatment groups and their 
negative control groups. P-values of < 0.05 were considered to be statistically significant. 
3. Results 
Treatment of P3-X63-Ag8.653 mouse myeloma cells with rTNF-ǂ showed a statistically 
significant reduction in cell viability in comparison with negative control cells. The 
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reduction in cell viability occurred in dose-dependent manner, with higher doses having a 
greater effect (Table 1, Figures 1-4). Treatment of P3-X63-Ag8.653 mouse myeloma cells with 
400, 800 and 1200 IU/ml of rTNF-ǂ showed a complete cessation of cell growth (Table 1), 
with the cells being unable to enter the log phase of the S-shaped growth curve (Figure 4). 
Treatment of P3-X63-Ag8.653 mouse myeloma cells with a combination of rTNF-ǂ and 
nhIFN-ǂ showed a statistically significant reduction in cell viability in comparison with 
negative control cells and cells treated exclusively with either rTNF-ǂ or nhIFN-ǂ. The 
addition of a small dose of rTNF-ǂ (10 IU/ml) to the treatment of P3-X63-Ag8.653 mouse 
myeloma cells with a relatively high dose of nhIFN-ǂ (2000 IU/ml) resulted in a further, 
although small, reduction in cell viability (Table 1, Figure 5). 
 
Cell study 
group 
Cytokine type 
Cytokine 
concentration 
(IU/ml) 
No. of cells (104/ml)
Mean +/- SE  
over days 0-4 
Statistical 
significance1 
rTNF-α (1)  Negative control 20.400 +/- 0.83306 P = 0.001 
 rTNF-α 2 20.187 +/- 1.65707  
 rTNF-α 10 16.675 +/- 1.99607  
 rTNF-α 20 13.425 +/- 0.54608  
rTNF-α (2)  Negative control 23.3250 +/- 1.96338 P = 0.000 
 rTNF-α 30 12.8750 +/- 0.55234  
 rTNF-α 40 10.4250 +/- 0.71709  
 rTNF-α 50 9.3750 +/- 0.20444  
rTNF-α (3)  Negative control 22.9000 +/- 0.79096 P = 0.000 
 rTNF-α 100 8.5125 +/- 0.32918  
 rTNF-α 200 5.9625 +/- 0.34403  
 rTNF-α 300 1.6750 +/- 0.07500  
rTNF-α (4)  Negative control 22.2000 +/- 1.16011 P = 0.000 
 rTNF-α 400 1.0375 +/- 0.05078  
 rTNF-α 800 0.9250 +/- 0.06673  
 rTNF-α 1200 0.6750 +/- 0.03644  
rTNF-α and 
nhIFN-α  Negative control 25.9625 +/- 0.62581 P = 0.000 
 rTNF-α 10 19.6375 +/- 1.07591  
 nhIFN-α 2000 5.8000 +/- 0.10346  
 
rTNF-α and 
nhIFN-α 10 and 2000 4.8500 +/- 0.35609  
1Comparison between active treatment overall and the corresponding negative control in each cell 
study group. 
Table 1. Effect of recombinant human tumor necrosis factor-ǂ (rTNF-ǂ) at different 
concentrations, native human interferon-ǂ (nhIFN-ǂ) and the combination of rTNF-ǂ and 
nhIFN-ǂ on in-vitro P3-X63-Ag8.653 mouse myeloma cell growth. 
As expected, when the cell numbers for each cell study group of P3-X63-Ag8.653 mouse 
myeloma cells treated with the different concentrations of rTNF-ǂ and with the combination 
of rTNF-ǂ and nhIFN-ǂ or their negative controls were plotted on a logarithmic scale for the 
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whole 96 hours (four days) period over which cell viability was measured, the growth 
curves were S-shaped. P3-X63-Ag8.653 mouse myeloma cells started to enter the log phase 
at approximately 24 hours (one day) and reached the plateau phase at approximately 72 
hours (three days) from incubation with the different concentrations of rTNF-ǂ and with the 
combination of rTNF-ǂ and nhIFN-ǂ. The intermediate portions (log phase) of the S-shaped 
growth curves, approximately between 24 and 72 hours, were linear. The slopes of the 
growth curves in the treated cell culture study groups and their negative controls were not 
identical (Figures 1-5). 
 
Fig. 1. The effect of 2, 10 and 20 IU/ml of human recombinant TNF-ǂ (rTNF-ǂ) on in-vitro 
P3-X63-Ag8.653 mouse myeloma cell growth plotted on a logarithmic scale (logarithmic 
number of P3-X63-Ag8.653 cells/ml), showing a dose-dependent reduction in cell viability 
over four days of treatment. The reduction in cell growth observed with rTNF-ǂ was 
statistically significant in comparison with negative control (P = 0.001). Legend: black, day 0; 
green, day 1; light blue, day 2; dark blue, day 3; violet, day 4. 
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Fig. 2. The effect of 30, 40 and 50 IU/ml of human recombinant tumor necrosis factor-ǂ 
(rTNF-ǂ) on in-vitro P3-X63-Ag8.653 mouse myeloma cell growth plotted on a logarithmic 
scale (logarithmic number of P3-X63-Ag8.653 cells/ml), showing a dose-dependent 
reduction in cell viability over four days of treatment. The reduction in cell growth observed 
with rTNF-ǂ was statistically significant in comparison with negative control (P = 0.000). 
Legend: black, day 0; green, day 1; light blue, day 2; dark blue, day 3; violet, day 4. 
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Fig. 3. The effect of 100, 200 and 300 IU/ml of human recombinant TNF-ǂ (rTNF-ǂ) on in-
vitro P3-X63-Ag8.653 mouse myeloma cell growth plotted on a logarithmic scale 
(logarithmic number of P3-X63-Ag8.653 cells/ml), showing a dose-dependent reduction in 
cell viability over four days of treatment. The reduction in cell growth observed with rTNF-
ǂ was statistically significant in comparison with negative control (P = 0.000). Legend: black, 
day 0; green, day 1; blue, day 2; light violet, day 3; dark violet, day 4. 
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Fig. 4. The effect of 400, 800 and 1200 IU/ml of human recombinant TNF-ǂ (rTNF-ǂ) on in-
vitro P3-X63-Ag8.653 mouse myeloma cell growth plotted on a logarithmic scale 
(logarithmic number of P3-X63-Ag8.653 cells/ml), showing a dose-dependent reduction in 
cell viability over four days of treatment. The reduction in cell growth observed with  
rTNF-ǂ was statistically significant in comparison with negative control (P = 0.000).  
Legend: black, day 0; green, day 1; light blue, day 2; dark blue, day 3; violet, day 4. 
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Fig. 5. The effect of 10 IU/ml of human recombinant TNF-ǂ (rTNF-ǂ), 2000 IU/ML of native 
human leukocyte interferon-ǂ (nhIFN-ǂ), and of a combination of 10 IU/ml of rTNF-ǂ and 
2000 IU/ML of nhIFN-ǂ on in-vitro P3-X63-Ag8.653 mouse myeloma cell growth plotted on 
a logarithmic scale (logarithmic number of P3-X63-Ag8.653 cells/ml), showing a reduction 
in cell viability over four days of treatment. The reduction in cell growth observed after 
treatment with rTNF-ǂ, nhIFN-ǂ, and with the combination of rTNF-ǂ and nhIFN-ǂ, was 
statistically significant in comparison with negative control (P = 0.000). Legend: black, day 0; 
green, day 1; light blue, day 2; dark blue, day 3; violet, day 4. 
4. Discussion 
Treatment with rTNF-ǂ at different doses had a negative effect on in vitro P3-X63-Ag8.653 
mouse myeloma cell growth. A statistically significant dose-dependent reduction in cell 
viability was observed in P3-X63-Ag8.653 mouse myeloma cells treated with rTNF-ǂ in 
comparison with negative controls. Additionally, a slightly enhanced reduction in P3-X63-
Ag8.653 mouse myeloma cell viability was observed in cells treated with the combination of 
rTNF-ǂ and nhIFN-ǂ, in comparison with negative controls and cells treated exclusively 
with either rTNF-ǂ or nhIFN-ǂ. 
The results of this study are surprising, as the treatment of P3-X63-Ag8.653 mouse myeloma 
with rTNF-ǂ showed statistically significant reduction in cell viability compared with 
untreated control cells, with higher doses having greater effect. These results are in 
contradiction with numerous reports describing TNF-ǂ as a survival and proliferation factor 
in MM (Harrison et al., 2006; Hideshima et al., 2004; Jourdan et al., 1999; Yasui et al., 2006; 
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Westendorf et al., 1996). However, TNF-ǂ has previously also been described as an 
apoptotic factor in MM. The TNF-dependent trimerization of TNF receptors may lead to the 
recruitment of TRADD (TNF-R1 associated death domain protein), FADD (Fas-associated 
death domain protein) or RIP (receptor interacting protein) adapter proteins, resulting in 
activation and acceleration of caspase cascade (Baker & Reddy, 1996; Dai et al., 2003; 
Jourdan et al., 1999). This mechanism may further lead to apoptosis in MM cells (Jourdan et 
al., 1999).  
Treatment of P3-X63-Ag8.653 mouse myeloma cells with the combination of rTNF-ǂ and 
nHIFN-ǂ resulted in an enhancement of the reduction in cell viability in comparison with 
negative control cells and cells treated exclusively with either rTNF-ǂ or nhIFN-ǂ. The 
nHIFN-ǂ used in this study contains traces of a number of other cytokines produced by 
human peripheral blood leukocytes infected by Sendai virus (Šantak et al., 2007, Zidovec & 
Mažuran, 1999). The differences between the slopes of the S-shaped growth curves in the 
rTNF-ǂ treated P3-X63-Ag8.653 mouse myeloma cell cultures and their controls, and equally 
prominent differences between the slopes of the growth curves of cells treated with the 
combination of rTNF-ǂ and nHIFN-ǂ and corresponding doses of single cytokines and their 
controls, may indicate that the active mechanisms associated with rTNF-ǂ and nHIFN-ǂ, 
and involved in reduction of cell viability, share some similarities and may possibly benefit 
from the synergy between rTNF-ǂ, various subtypes of IFN-ǂ and the small amounts of a 
number of other cytokines in the nHIFN-ǂ preparation (Desmyter et al., 1968; Plesničar et 
al., 2009). In this context, it would be interesting to identify whether TNF-ǂ and IFN-ǂ share 
any signaling pathways leading to the reduction in MM cell viability and MM cell death. 
Contrary to expectations, in this study treatment of P3-X63-Ag8.653 mouse myeloma cells 
with rTNF-ǂ showed no increase, but a significant dose-dependent reduction in their cell 
viability. The P3-X63-Ag8.653 mouse myeloma cells propagate in suspension and show 
lymphocyte-like morphology (Kearney et al., 1979), and with this in mind, these cells may 
perhaps be useful in assessment of the effects rTNF-ǂ may have on the growth of clonogenic 
B-cells in blood of patients with MM. Clonogenic B-cells represent the proliferating 
compartment in MM and possibly also a biologically distinct, drug-resistant MM progenitor 
population responsible for cell growth in tumor relapse after the treatment (Matsui et al., 
2004; Matsui et al., 2008). In comparison to terminally differentiated plasma cells in MM, 
clonogenic B-cells appear to be relatively resistant to a number of anti-cancer agents, 
including dexamethasone, bortezomib, lenalidomide, and 4-hydroxycyclophosphamide 
(Agarwal & Matsui, 2010; Matsui et al., 2008). Possible similarities between P3-X63-Ag8.653 
mouse myeloma cells and clonogenic B-cells in patients with MM, and because clonogenic 
B-cells are insensitive to standard cytotoxic chemotherapy and dexamethasone (Matsui et 
al., 2008), render the results observed in this study quite intriguing.  
It is known that the activity of TNF-ǂ as a survival and proliferation factor for MM is a part 
of a complex network of interactions between MM plasma cells, stromal cells and other cells 
in BM (Jourdan et al., 1999; Matsui et al., 2008). In this in vitro study, P3-X63-Ag8.653 mouse 
myeloma cells were grown in suspension culture, probably resembling the circumstances in 
which clonogenic B-cells in patients with MM grow without influences of BM 
microenvironment (Matsui et al., 2008). In a number of studies, serum levels of TNF-ǂ were 
shown to be increased in patients with active MM and manifest bone disease, and to be 
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associated with poor prognosis (Alexandrakis et al., 2004; Fillela et al., 1996; Jourdan et al., 
1999). Hypothetically, it may be possible to speculate that the increased serum levels of 
TNF-ǂ in patients with active MM represent a part of a complex negative control loop 
mechanism that regulates and negatively affects the quantity of circulating clonogenic B-
cells in such patients. 
A heterologous system was used to evaluate the effects of rTNF-ǂ and its combination with 
nHIFN-ǂ on MM cells in-vitro. Recombinant human tumor necrosis factor-ǂ and nHIFN-ǂ 
used in this study were active in P3-X63-Ag8.653 mouse myeloma cells, again confirming 
the observations that cytokines synthesized in cells of one species may have a considerable 
effect in cells of another closely related species (Desmyter et al., 1968; Greenberg & Mosny, 
1977; Ozdemir et al., 2004). Moreover, MM cells are difficult to grow in vitro (Barker et al., 
1993). An important advantage of the P3-X63-Ag8.653 mouse myeloma cell line may also lie 
in its easy reproducibility, unlimited supply, infinite storability and recoverability, and 
consequently in important cost savings (Drexler & Matsuo, 2000). 
The results of this study point to the importance of the study of differential effects TNF-ǂ 
may exert on malignant cells in MM during specific phases of their development and 
differentiation. It is possible that TNF-ǂ may have a role in future carefully planned 
personalized therapy approaches based on genetic features, age, and other risk factors in 
patients with MM (Durie, 2008; Ludwig et al., 2008). Such therapy could perhaps include 
patients’ own TNF-ǂ, IFN-ǂ, other substances and their combinations, provided that 
effective procedures for the establishment and maintenance of ex vivo cell cultures of 
patients’ own cytokine-producing cells become available. 
5. Conclusion 
The results of this study point to the importance of assessing the role of TNF-ǂ in study and 
therapy of MM. Additional studies with other cytokines and human MM cells are required 
to obtain further information.  
6. References 
Agarwal, J.A. & Matsui, W. (2010). Multiple Myeloma: A Paradigm for Translation of the 
Cancer Stem Cell Hypothesis. Anti-Cancer Agents in Medicinal Chemistry, Vol.10, 
No.2, (February 2010), pp. 116-120, ISSN 1875-5992 
Alexandrakis, M.G., Passam, F.J., Ganotakis, E., Dafnis, E., Dambaki, C., Konsolas, J., 
Kyriakou, D.S. & Stathopoulos, E. (2004). Bone Marrow Microvascular Density and 
Angiogenic Growth Factors in Multiple Myeloma. Clinical Chemistry and Laboratory 
Medicine, Vol.42, No.10, (October 2004), pp. 1122-1126, ISSN 1434-6621 
Baker, S.J. & Reddy, E.P. (1996). Transducers of life and death: TNF Receptor Superfamily 
and Associated Proteins. Oncogene, Vol.12, No.1, (January 1996), pp. 1-9, ISSN 0950-
9232 
Barker, H.F., Ball, J., Drew, M. & Franklin, I.M. (1993). Multiple Myeloma: The Biology of 
Malignant Plasma Cells. Blood Reviews, Vol.7, No.1 (March 1993), pp.19-23. ISSN 
0268-960X 
www.intechopen.com
 
Multiple Myeloma – An Overview 
 
72
Bommert, K., Bargou, R.C. & Stühmer, T. (2006). Signalling and Survival Pathways in 
Multiple Myeloma. European Journal of Cancer, Vol.42, No.11, (July 2006), pp. 1574-
1580, ISSN 0014-2964 
Cheriyath, V., Glaser, K.B., Waring, J.F., Baz, R., Hussein, M.A. & Borden, E.C. (2007). G1P3, 
an IFN-Induced Survival Factor, Antagonizes TRAIL-Induced Apoptosis in Human 
Myeloma Cells. Journal of Clinical Investigation, Vol.117, No.10, (October 2007), pp. 
3107-3117, ISSN 0021-9738 
Cremer, F.W., Goldschmidt, H. & Moos, M. (2001). Clonotypic B Cells in the Peripheral 
Blood of Patients with Multiple Myeloma. Blood, Vol.97, No.9 (May 2001), pp. 2913-
2914, ISSN 1528-0020 
Dai, Y., Dent, P. & Grant, S. (2003). Tumor Necrosis Factor-Related Apoptosis-Inducing 
Ligand (TRAIL) Promotes  Mitochondrial dysfunction and Apoptosis Induced by 7-
Hydroxystauroporine and Mitogen-Activated Protein Kinase Inhibitors in Human 
Leukemia Cells That Ectopically Express Bcl-2 and Bcl-xL. Molecular Pharmacology, 
Vol.64, No.6, (December 2003), pp. 1402-1409, ISSN 0026-895X 
Desmyter, J., Rawls, W.E. & Melnick, J.L. (1968). A Human Interferon That Crosses the 
Species Line. Proceedings of the National Academy of Sciences of the United States of 
America, Vol.59, No.1, (January 1968), pp. 69-76, ISSN 0027-8424 
Drexler, H.G. & Matsuo, Y. (2000). Malignant Hematopoietic Cell Lines: In Vitro Models for 
the Study of Multiple Myeloma and Plasma Cell Leukemia. Leukemia Research, 
Vol.24, No.8, (August 2000), pp. 681–703, ISSN 0145-2126 
Durie, B.G.M. (2008). Myeloma therapy: 25 Years Forward-Immune Modulation Then and 
Now. Journal of Clinical Oncology, Vol.26, No.29, (October 2008), pp. 4698-4700, ISSN 
1527-7755 
Ferlin-Bezombes, M., Jourdan, M., Liautard, J., Brochier, B., Rossi, J.F. & Klein, B. (1998). 
IFN-Alpha is a Survival Factor for Human Myeloma Cells and Reduces 
Dexamethasone-Induced Apoptosis. Journal of Immunology, Vol.161, No.6, 
(September 1998), pp. 2692-2699, ISSN 0022-1767 
Fillela, X., Blade, J., Guillermo, A.L., Molina, R., Rozman, C. & Ballesta, A.M. (1996). 
Cytokines (IL-6, TNF-alpha, IL-1alpha) and Soluble IL-2 Receptor as Serum Tumor 
Markers in Multiple Myeloma. Cancer Detection and Prevention, Vol.20, No.1, 
(January 1996), pp. 52-56, ISSN 1525-1500 
Greenberg, P.L. & Mosny, S.A. (1977). Cytotoxic Effects of Interferon In Vitro on 
Granulocytic Progenitor Cells. Cancer Research, Vol.37, No.6, (June 1977), pp. 1794-
1799, ISSN 0008-5472 
Harrison, S.J., Cook, G., Nibbs, R.J.B. & Miles Prince, H. (2006). Immunotherapy of Multiple 
Myeloma: The Start of a Long and Tortuous Journey. Expert Review of Anticancer 
Therapy, Vol.6, No.12, (December 2006), pp. 1769-1785, ISSN 1473-7140 
Hideshima, T., Bergsagel P.L., Kuehl W.M. & Anderson, K.C. (2004). Advances in Biology of 
Multiple Myeloma: Clinical Applications. Blood, Vol.104, No.3 (August 2004), pp. 
607-618, ISSN 1528-0020 
Jourdan, M., Tarte, K., Legouffe, E., Brochier, J., Rossi, J.F. & Klein, B. (1999). Tumor 
Necrosis Factor is a Survival and Proliferation Factor for Human Myeloma Cells. 
European Cytokine Network, Vol.10, No.1, (March 1999), pp. 65-70, ISSN 1148-5493 
www.intechopen.com
Effects of Recombinant Human Tumor Necrosis Factor-α and Its Combination  
with Native Human Leukocyte Interferon-α on P3-X63-Ag8.653 Mouse Myeloma Cell Growth 
 
73 
Katzel, J.A., Hari, P. & Vesole, D.H. (2007). Multiple Myeloma; Charging Toward Bright 
Future. CA Cancer Journal for Clinicians, Vol.57, No.5, (September/October 2007), 
pp. 301-318, ISSN 1542-4863 
Kearney, J.F., Radbruch A., Liesegang B. & Rajewsky, K. (1979). A New Mouse Myeloma 
Cell Line That has Lost Immunoglobulin Expression but Permits the Construction 
of Antibody-Secreting Hybrid Cell Lines. Journal of Immunology. Vol.123, No.4, 
(October 1979), pp. 1548-1550, ISSN 0022-1767 
Ludwig, H., Durie, B.G.M., Bolejack, V., Turesson, I., Kyle, R.A., Blade, J., Fonseca, R., 
Dimopoulos, P., Shimizu, K., San Miguel, J., Westin, J., Harousseau, J.L., Beksac, M., 
Boccadoro, M., Palumbo, A., Barlogie, B., Shustik, C., Cavo, M., Greipp, P.R., 
Joshua, D., Attal, M., Sonneveld, P. & Crowley, J. (2008). Myeloma in Patients 
Younger than Age 50 Years Presents with More Favorable Features and Shows 
Better Survival: An Analysis of 10,549 Patients from the International Myeloma 
Working Group. Blood, Vol.111, No.8, (April 2008), pp. 4039-4047, ISSN 1528-0020 
Matsui, W., Huff, C.A., Wang, Q., Malehorn M.T., Barber, J., Tanhehco, Y., Smith, B.D., 
Civin, C.I. & Jones, R.J. (2004). Characterization of Clonogenic Multiple Myeloma 
Cells. Blood, Vol.103, No. 6, (March 2004), pp. 2332-2336, ISSN 1528-0020 
Matsui, W., Wang, Q., Barber J.P., Brennan, J.P., Brennan, S., Douglas Smith, S., Borrello, I, 
McNiece, I., Lin, L., Ambinder, R.F., Peacock, C., Watkins, D.N., Huff, C.A. & Jones, 
R.J. (2008). Clonogenic Multiple Myeloma Progenitors, Stem Cell Properties, and 
Drug Resistance. Cancer Research, Vol.68, No.1, (January 2008), pp. 190-197, ISSN 
0008-5472 
Mellstedt, H., Holm, G. & Björkholm, M. (1984). Multiple Myeloma, Waldenström’s 
Macroglobulinemia, and Benign Monoclonal Gammopathy; Characteristics of the B 
Cell Clone, Immunoregulatory Cell Populations and Clinical Implications. Advances 
in Cancer Research, Vol.41, No.00, (Frequency Annual, 1984), pp. 257-289, ISSN 0065-
230X 
Ozdemir, F., Esen, N., Ovali, E., Tekelioglu, Y., Yilmaz, M., Aydin, F., Kavgaci, H. & 
Boruban, C. (2004). Effects of Dexamethasone, All-Trans Retinoic Acid, Vitamin D3 
and Interferon-ǂ on FO Myeloma Cells. Chemotherapy, Vol.50, No.4 (September 
2004), pp. 190-193, ISSN 0009-3157 
Plesničar, A., Vidmar, G., Štabuc, B. & Kores Plesničar, B. (2009). Effects of Native Human 
Leukocyte Interferon-ǂ on P3-X63-Ag8.653 Mouse Myeloma Cell Growth. The 
Journal of International Medical Research, Vol.37, No.5 (September/October 2009), pp. 
1570-1576, ISSN 0300-0605 
Puthier, D., Thabard, W., Rapp, M., Etrillard, M., Harosseau, J., Bataille, R. & Amiot, M. 
(2001). Interferon Alpha Extends the Survival of Human Myeloma Cells Through 
an Upregulation of the Mcl-1 Anti-Apoptotic Molecule. British Journal of 
Haematology, Vol.112, No.2, (February 2001), pp. 358-363, ISSN 1365-2141 
Raman, D., Baugher, P.J., Thu, Y.M. & Richmond, A. (2007). Role of Chemokines in Tumor 
Growth. Cancer Letters, Vol.256, No.2, (July 2007), pp. 137-165, ISSN 0304-3835 
Redzepovic, J., Weimann, G., Ott, I. & Gust, R. (2008). Current Trends in Multiple Myeloma 
Management. The Journal of International Medical Research, Vol.36, No.3, (May/June 
2008), pp. 371-386, ISSN 0300-0605 
Sawamura, M., Murayama, K., Ui, G., Matsushima, T., Tamura, J., Murakami, H., Naruse, T. 
& Tsuchiya, J. (1992). Plasma Cell Leukaemia with Alpha-Interferon Therapy in 
www.intechopen.com
 
Multiple Myeloma – An Overview 
 
74
Myeloma. British Journal of Haematology, Vol.82, No.3, (November 1992), pp. 631, 
ISSN 1365-2141 
Silvestris, F., Cafforio, P., Calvani, N. & Dammaco, M. (2004). Impaired Osteoblastogenesis 
in Myeloma Bone Disease: Role of Upregulated Apoptosis by Cytokines and 
Malignant Plasma Cells. British Journal of Haematology, Vol.126, No.4, (August 2004), 
pp. 475-486, ISSN 1365-2141 
Šantak, G., Šantak, M. & Forčić, D. (2007). Native Human IFN-ǂ is a More Potent Suppressor 
of HDF Response to Profibrotic Stimuli Than Recombinant human IFN-ǂ. Journal of 
Interferon & Cytokine Research: the Official Journal of the International Society for 
Interferon and Cytokine Research, Vol.27, No.6, (June 2007), pp. 481-490, ISSN 1079-
9907 
Westendorf, J.J., Ahmann G.J., Greipp, J.R., Witzig, T.E., Lust, J.A. & Jelinek, D.F. (1996). 
Establishment and Characterization of Three Myeloma Cell Lines That 
Demonstrate Variable Cytokine Responses and Abilities to Produce Autocrine 
Interleukin-6. Leukemia, Vol. 10, No.5, (May 1996), pp. 866-876, ISSN 0887-6924 
Wilson, A.P. (1994). Cytotoxicity and Viability Assays. In: Animal Cell Culture. A Practical 
Approach, 2nd edn. Freshney RI Editor, pp. 263-303, Oxford University Press, ISBN 0 
19 963212 X (Hbk), Oxford 
Yasui, H., Hideshima, T., Richardson P.G. & Anderson, K.C. (2006). Novel Therapeutic 
Strategies Targeting Growth Factor Signaling Cascades in Multiple Myeloma. 
British Journal of Haematology, Vol.132, No.4, (February 2006), pp. 385-397, ISSN 
1365-2141 
Zidovec, S. & Mažuran, R. (1999). Sendai Virus Induces Various Cytokines in Human 
Peripheral Blood Leukocytes: Different Susceptibility of Cytokine Molecules to 
Low pH. Cytokine, Vol.11, No.2, (February 1999), pp. 140–143, ISSN 1043-4666 
www.intechopen.com
Multiple Myeloma - An Overview
Edited by Dr. Ajay Gupta
ISBN 978-953-307-768-0
Hard cover, 274 pages
Publisher InTech
Published online 20, January, 2012
Published in print edition January, 2012
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
Multiple myeloma is a malignant disorder characterized by the proliferation of plasma cells. Much insight has
been gained into the molecular pathways that lead to myeloma and indeed much more remains to be done.
The understanding of these pathways is closely linked to their therapeutic implications and is stressed upon in
the initial chapters. Recently, the introduction of newer agents such as bortezomib, lenalidomide, thalidomide,
liposomal doxorubicin, etc. has led to a flurry of trials aimed at testing various combinations in order to improve
survival. Higher response rates observed with these agents have led to their integration into induction
therapies. The role of various new therapies vis a vis transplantation has also been examined. Recent
advances in the management of plasmacytomas , renal dysfunction, dentistry as well as mobilization of stem
cells in the context of myeloma have also found exclusive mention. Since brevity is the soul of wit our attempt
has been to present before the reader a comprehensive yet brief text on this important subject.
How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
Andrej Plesničar, Gaj Vidmar, Borut Štabuc and Blanka Kores Plesničar (2012). Effects of Recombinant
Human Tumor Necrosis Factor-α and Its Combination with Native Human Leukocyte Interferon-α on P3-X63-
Ag8.653 Mouse Myeloma Cell Growth, Multiple Myeloma - An Overview, Dr. Ajay Gupta (Ed.), ISBN: 978-953-
307-768-0, InTech, Available from: http://www.intechopen.com/books/multiple-myeloma-an-overview/effects-
of-recombinant-human-tumor-necrosis-factor-and-its-combination-with-native-human-leukocyte-i
© 2012 The Author(s). Licensee IntechOpen. This is an open access article
distributed under the terms of the Creative Commons Attribution 3.0
License, which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
